Literature DB >> 2651532

Lipopolysaccharide (LPS)-reactive monoclonal antibodies fail to inhibit LPS-induced tumor necrosis factor secretion by mouse-derived macrophages.

J K Chia1, M Pollack, G Guelde, N L Koles, M Miller, M E Evans.   

Abstract

Murine monoclonal antibodies (MAbs) reactive with epitopes on the O-side chain, core oligosaccharide, or lipid A of Escherichia coli and Salmonella minnesota lipopolysaccharide (LPS) were evaluated for their ability to inhibit LPS-induced tumor necrosis factor (TNF) secretion by mouse-derived RAW 264.7 macrophages. As little as 50 ng of purified LPS or lipid A stimulated macrophages to produce TNF detectable as cytotoxic activity in an L-929 fibroblast assay. None of 13 MAbs (concentration range, 0.1-1,000 micrograms/mL) blocked LPS- or lipid A (0.025-0.1 micrograms/mL)-induced TNF secretion by RAW 264.7 cells. Rabbit antiserum to synthetic lipid A also failed to block lipid A-induced TNF activity. Similar negative results were obtained when intact bacteria or membrane vesicles were used as TNF inducers. In contrast, polymyxin B, but not the less hydrophobic polymyxin B nonapeptide, produced almost complete inhibition of macrophage TNF secretion induced by LPS, lipid A, membrane vesicles, and intact bacteria. Thus, antibody reactivity with predominantly hydrophilic elements of LPS or lipid A may not affect hydrophobic interactions between lipid A and target cell membranes necessary and sufficient for the induction of TNF. These findings raise doubts concerning the existence of true endotoxin-neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651532     DOI: 10.1093/infdis/159.5.872

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS.

Authors:  H Loppnow; P Libby; M Freudenberg; J H Krauss; J Weckesser; H Mayer
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

2.  Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Pollack; N L Koles; M J Preston; B J Brown; G B Pier
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

3.  Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis.

Authors:  S M Opal; A S Cross; J C Sadoff; H H Collins; N M Kelly; G H Victor; J E Palardy; M W Bodmer
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

4.  Cytokine response in mouse bone marrow derived macrophages after infection with pathogenic and non-pathogenic Rift Valley fever virus.

Authors:  Kimberly K Roberts; Terence E Hill; Melissa N Davis; Michael R Holbrook; Alexander N Freiberg
Journal:  J Gen Virol       Date:  2015-03-10       Impact factor: 3.891

5.  Inhibition of lipopolysaccharide-associated endotoxin activities in vitro and in vivo by the human anti-lipid A monoclonal antibody SdJ5-1.17.15.

Authors:  I S Fang; M A Wisniewski; C C Huntenburg; L S Knight; J E Bubbers; M J Schneidkraut
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

6.  A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides.

Authors:  F E Di Padova; H Brade; G R Barclay; I R Poxton; E Liehl; E Schuetze; H P Kocher; G Ramsay; M H Schreier; D B McClelland
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

7.  The anti-lipid A monoclonal antibody E5 binds to rough gram-negative bacteria, fixes C3, and facilitates binding of bacterial immune complexes to both erythrocytes and monocytes.

Authors:  M A Seelen; P Athanassiou; W A Lynn; P Norsworthy; M J Walport; J Cohen; K A Davies
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

8.  Is nitric oxide decrease observed with naphthoquinones in LPS stimulated RAW 264.7 macrophages a beneficial property?

Authors:  Brígida R Pinho; Carla Sousa; Patrícia Valentão; Paula B Andrade
Journal:  PLoS One       Date:  2011-08-26       Impact factor: 3.240

9.  Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies.

Authors:  J D Baumgartner; D Heumann; J Gerain; P Weinbreck; G E Grau; M P Glauser
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.